化合物 T10228 T10228

Product Introduction
Bioactivity


英文名: AC710 Mesylate

描述: AC710 Mesylate is a potent PDGFR inhibitor (Kds: 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ).

动物实验: The antitumor efficacy of AC710 is assessed in a subcutaneous flank-tumor xenograft model in athymic nude mice using the MV4-11cell line. AC710 is dosed at 0.3, 3, and 30 mg/kg for 2 weeks. Tumor growth and body weight are monitored.

体内活性: At 0.3 mg/kg of AC710, tumor growth is temporally inhibited, and growth resumes quickly thereafter. At 3 and 30 mg/kg of AC710, tumors regress completely, and the tumor volume stays suppressed for an extended period after dosing is halted. No bodyweight loss is observed in animals treated with AC710 at all doses, indicating that it is well tolerated in mice at efficacious doses. AC710 exhibits a significant impact on disease in a dose-dependent fashion in a mouse collagen-induced arthritis (CIA) model, at a dose as low as 3 mg/ kg for 15 days (day 0-14). AC710 (10 and 30 mg/kg) demonstrates equivalent or slightly better efficacy in reducing the joint swelling and inflammation than dexomethasone administered at a safe dose.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: AC710 Mesylate | AC-710 Mesylate | AC 710 Mesylate

相关产品: Avapritinib | Cediranib | SU 5402 | Sennoside B | 5Z-7-Oxozeaenol | Eupatolide | CP-673451 | PDGFRα kinase inhibitor 1 | Amuvatinib | Imatinib

化合物 T10228 T10228信息由TargetMol中国为您提供，如您想了解更多关于化合物 T10228 T10228报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途